Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 4/20 | 0.63 |
| ▸ | NPC1 | O15118 | 3/20 | 0.63 |
| ▸ | POLB | P06746 | 2/20 | 0.63 |
| ▸ | EPHX2 | P34913 | 6/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | HTT | P42858 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16866144 | 0.84 | NPC1 (0.86) | RAB9ANPC1POLBEPHX2KMT2A | |
| SCHEMBL12810855 | 0.80 | NPC1 (0.42) | RAB9ANPC1POLBEPHX2KMT2A | |
| SCHEMBL13825680 | 0.80 | NPC1 (0.42) | RAB9ANPC1POLBEPHX2KMT2A | |
| SCHEMBL23573491 | 0.79 | NPC1 (0.77) | RAB9ANPC1POLBEPHX2KMT2A | |
| SCHEMBL23573490 | 0.79 | NPC1 (0.77) | RAB9ANPC1POLBEPHX2KMT2A | |
| SCHEMBL2750640 | 0.79 | RAB9A (0.97) | RAB9ANPC1POLBEPHX2KMT2A | |
| SCHEMBL3332514 | 0.78 | KMT2A (0.68) | POLBKMT2ASMN1; SMN2GAAALDH1A1 | |
| SCHEMBL14257414 | 0.78 | NPC1 (0.41) | RAB9ANPC1POLBEPHX2KMT2A | |
| SCHEMBL12810857 | 0.78 | NPC1 (0.41) | RAB9ANPC1POLBEPHX2KMT2A | |
| SCHEMBL27267057 | 0.78 | RAB9A (1.00) | RAB9ANPC1POLBEPHX2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109336884-B | Method for synthesizing trametinib key intermediate | 安庆奇创药业有限公司 | 2021-02-05 | — | — | CN | claimed |
| US-20220380362-A1 | PYRIMIDINE COMPOUND AND MEDICAL USE THEREOF | JAPAN TOBACCO INC. (JP) | 2022-12-01 | — | — | US | disclosed |
| CN-109336884-B | Method for synthesizing trametinib key intermediate | 安庆奇创药业有限公司 | 2021-02-05 | — | — | CN | disclosed |
| CN-109336884-B | Method for synthesizing trametinib key intermediate | 安庆奇创药业有限公司 | 2021-02-05 | — | — | CN | disclosed |
| WO-2020161654-A1 | A PROCESS FOR THE PREPARATION OF TRAMETINIB ACETIC ACID SOLVATE | AUROBINDO PHARMA LIMITED (IN) | 2020-08-13 | — | — | WO | disclosed |
| US-20200109139-A1 | PYRIMIDINE COMPOUND AND MEDICAL USE THEREOF | JAPAN TOBACCO INC. (JP) | 2020-04-09 | — | — | US | disclosed |
| US-20200109139-A1 | PYRIMIDINE COMPOUND AND MEDICAL USE THEREOF | JAPAN TOBACCO INC. (JP) | 2020-04-09 | — | — | US | disclosed |
| US-20180273531-A1 | PYRIMIDINE COMPOUND AND MEDICAL USE THEREOF | JAPAN TOBACCO INC. (JP) | 2018-09-27 | — | — | US | disclosed |
| US-20170029418-A1 | PYRIMIDINE COMPOUND AND MEDICAL USE THEREOF | JAPAN TOBACCO INC. (JP) | 2017-02-02 | — | — | US | disclosed |
| US-20170029418-A1 | PYRIMIDINE COMPOUND AND MEDICAL USE THEREOF | JAPAN TOBACCO INC. (JP) | 2017-02-02 | — | — | US | disclosed |
| US-7378423-B2 | Antiproliferative, anticancer, antitumor agents; rheumatism; N-{3-[3-cyclopropyl-5-(2-fluoro-4-iodo-phenylamino)-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydro-2H-pyrido[4,3-d]pyrimidin-1-yl]-phenyl}-acetamide; a p15, and/or a protein inducing action, and/or an MEK inhibitory action; side effect reduction | JAPAN TOBACCO INC. (JP) | 2008-05-27 | — | — | US | disclosed |
| US-7378423-B2 | Antiproliferative, anticancer, antitumor agents; rheumatism; N-{3-[3-cyclopropyl-5-(2-fluoro-4-iodo-phenylamino)-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydro-2H-pyrido[4,3-d]pyrimidin-1-yl]-phenyl}-acetamide; a p15, and/or a protein inducing action, and/or an MEK inhibitory action; side effect reduction | JAPAN TOBACCO INC. (JP) | 2008-05-27 | — | — | US | disclosed |
| EP-1894932-A1 | 5-amino-2,4,7-trioxo-3,4,7,8-tetrahydro-2H-pyrido[2,3-d]pyrimidine derivatives and related compounds for the treatment of cancer | Japan Tobacco, Inc. (JP) | 2008-03-05 | — | — | EP | disclosed |
| EP-1894932-A1 | 5-amino-2,4,7-trioxo-3,4,7,8-tetrahydro-2H-pyrido[2,3-d]pyrimidine derivatives and related compounds for the treatment of cancer | Japan Tobacco, Inc. (JP) | 2008-03-05 | — | — | EP | disclosed |
| EP-1761528-B1 | 5-AMINO-2,4,7-TRIOXO-3,4,7,8-TETRAHYDRO-2H-PYRIDO[2,3-D]PYRIMIDINE DERIVATIVES AND RELATED COMPOUNDS FOR THE TREATMENT OF CANCER | JAPAN TOBACCO INC (JP) | 2008-01-09 | — | — | EP | disclosed |
| EP-1761528-B1 | 5-AMINO-2,4,7-TRIOXO-3,4,7,8-TETRAHYDRO-2H-PYRIDO[2,3-D]PYRIMIDINE DERIVATIVES AND RELATED COMPOUNDS FOR THE TREATMENT OF CANCER | JAPAN TOBACCO INC (JP) | 2008-01-09 | — | — | EP | disclosed |
| CN-101006086-A | 5-amino-2, 4, 7-trioxo-3, 4,7, 8-tetrahydro-2H-pyrido [2, 3-d ] pyrimidine derivatives and related compounds for the treatment of cancer | JAPAN TOBACCO INC (JP) | 2007-07-25 | — | — | CN | disclosed |
| EP-1761528-A1 | 5-AMINO-2,4,7-TRIOXO-3,4,7,8-TETRAHYDRO-2H-PYRIDO[2,3-D]PYRIMIDINE DERIVATIVES AND RELATED COMPOUNDS FOR THE TREATMENT OF CANCER | Japan Tobacco, Inc. (JP) | 2007-03-14 | — | — | EP | disclosed |
| US-20060014768-A1 | Antiproliferative, anticancer, antitumor agents; rheumatism; N-{3-[3-cyclopropyl-5-(2-fluoro-4-iodo-phenylamino)-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydro-2H-pyrido[4,3-d]pyrimidin-1-yl]-phenyl}-acetamide; a p15, and/or a protein inducing action, and/or an MEK inhibitory action; side effect reduction | JAPAN TOBACCO INC. (JP) | 2006-01-19 | — | — | US | disclosed |
| WO-2005121142-A1 | 5-AMINO-2,4,7-TRIOXO-3,4,7,8-TETRAHYDRO-2H-PYRIDO’2,3-D! PYRIMIDINE DERIVATIVES AND RELATED COMPOUNDS FOR THE TREATMENT OF CANCER | JAPAN TOBACCO INC. (JP) | 2005-12-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220380362-A1 | PYRIMIDINE COMPOUND AND MEDICAL USE THEREOF | TYMP, TYMS, DPYD | RAB9A 4166/4885NPC1 3190/4885POLB 432/4885 |
| US-20180273531-A1 | PYRIMIDINE COMPOUND AND MEDICAL USE THEREOF | TYMP, TYMS, DPYD | RAB9A 4166/4885NPC1 3190/4885POLB 432/4885 |
| US-20170029418-A1 | PYRIMIDINE COMPOUND AND MEDICAL USE THEREOF | TYMP, TYMS, DPYD | RAB9A 4166/4885NPC1 3190/4885POLB 432/4885 |
| US-20060014768-A1 | Antiproliferative, anticancer, antitumor agents; rheumatism; N-{3-[3-cyclopropyl-5-(2-fluoro-4-iodo-phenylamino)-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydro-2H-pyrido[4,3-d]pyrimidin-1-yl]-phenyl}-acetamide; a p15, and/or a protein inducing action, and/or an MEK inhibitory action; side effect reduction | CDKN1A, CDK2, CDC25A | RAB9A 2902/4885NPC1 4705/4885POLB 1267/4885 |
| US-20200109139-A1 | PYRIMIDINE COMPOUND AND MEDICAL USE THEREOF | TYMP, TYMS, DPYD | RAB9A 4166/4885NPC1 3190/4885POLB 432/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.